12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Other News

Videregen Ltd., Cell Therapy Catapult, NHS Blood and Transplant (NHSBT), Royal Free London NHS Foundation, University College London (UCL) gene/cell therapy, pu

A consortium led by Videregen was awarded almost £2 million ($3.1 million) from the U.K.'s Technology Strategy Board through its regenerative medicine and cell therapy competition to develop Videregen's stem cell-based trachea replacement technology to treat severe structural airway disease (SSAD). The consortium will use the funds to develop and conduct early clinical trials...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >